Regulatory Status

December 2009: MGVS had completed patient enrollment and treatment in the phase I/IIa study of MultiGeneAngio for PAD patients with severe claudication in two leading US medical centers. Preliminary assessment demonstrated promising safety and clinical results.

December 2009: MGVS relocated to its new GMP production facility in Nesher, Israel, where MultiGeneAngio is being manufactured for advanced studies in Israel.

December 2009: MGVS received a green light from the Israeli Ministry of Health to begin a second phase I/IIa study with MultiGeneAngio as treatment for critical limb ischemia, a more severe stage of PAD.

September 2010: Shaare Zedek and Bnei Zion medical centers were added as active sites to a total of 7 medical centers participating in the study.

October 2010: MGVS is moving ahead with the second phase I/IIa study with MGA, as treatment for critical limb ischemia. Manufacture and administration of MGA to 8 patients in Israel was successful, with no treatment-related adverse events.

October 2010: MGVS presented its primary clinical findings in the Annual Israeli Wound and Diabetic Foot Conference.